JP2711630B2 - External preparation for skin - Google Patents
External preparation for skinInfo
- Publication number
- JP2711630B2 JP2711630B2 JP6095740A JP9574094A JP2711630B2 JP 2711630 B2 JP2711630 B2 JP 2711630B2 JP 6095740 A JP6095740 A JP 6095740A JP 9574094 A JP9574094 A JP 9574094A JP 2711630 B2 JP2711630 B2 JP 2711630B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- scutellaria
- extract
- sample
- pigment component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 21
- 235000000346 sugar Nutrition 0.000 claims description 49
- 239000000049 pigment Substances 0.000 claims description 38
- 239000000284 extract Substances 0.000 claims description 31
- 241000207929 Scutellaria Species 0.000 claims description 27
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 15
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 15
- -1 flavonoid compound Chemical class 0.000 claims description 8
- 229930003935 flavonoid Natural products 0.000 claims description 4
- 235000017173 flavonoids Nutrition 0.000 claims description 4
- KLZXCZXGBHQLDM-YJQGPUDQSA-N Phenylglucose Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)C1=CC=CC=C1 KLZXCZXGBHQLDM-YJQGPUDQSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 206010000496 acne Diseases 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 15
- 208000002874 Acne Vulgaris Diseases 0.000 description 14
- 239000006210 lotion Substances 0.000 description 14
- 201000008937 atopic dermatitis Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 206010012438 Dermatitis atopic Diseases 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000002537 cosmetic Substances 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 208000017520 skin disease Diseases 0.000 description 7
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 6
- KGIJOOYOSFUGPC-XRXZHELTSA-N 5-hydroxyeicosatetraenoic acid Natural products CCCCCC=CCC=CCC=C\C=C\C(O)CCCC(O)=O KGIJOOYOSFUGPC-XRXZHELTSA-N 0.000 description 6
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 239000003463 adsorbent Substances 0.000 description 6
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 6
- 229940015301 baicalein Drugs 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000002304 perfume Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000007670 refining Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- 208000024780 Urticaria Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000401 methanolic extract Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 2
- 229960004068 hexachlorophene Drugs 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- QNVRIHYSUZMSGM-UHFFFAOYSA-N hexan-2-ol Chemical compound CCCCC(C)O QNVRIHYSUZMSGM-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000019713 millet Nutrition 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920005990 polystyrene resin Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 2
- 229960001325 triclocarban Drugs 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- WOKTZUYZAQUVEI-ARFBSJSSSA-N (2,4,5-trimethoxyphenyl) (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound COC=1C=C(C(=CC1OC)OC)OC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WOKTZUYZAQUVEI-ARFBSJSSSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 1
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- TZYRSLHNPKPEFV-UHFFFAOYSA-N 2-ethyl-1-butanol Chemical compound CCC(CC)CO TZYRSLHNPKPEFV-UHFFFAOYSA-N 0.000 description 1
- RKHRWGLENCONFM-UHFFFAOYSA-N 2-hydroxyheptadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCCCC=CC=CC=C(O)C(O)=O RKHRWGLENCONFM-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- XHCYBIGJUPTJRR-UHFFFAOYSA-N OC(=O)CC(C(O)=O)S(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O.CCCCCCCCCCCC[Na] XHCYBIGJUPTJRR-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 244000291414 Vaccinium oxycoccus Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- GVBNSPFBYXGREE-CXWAGAITSA-N Visnadin Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)[C@H](C)CC)C(C)(C)O1 GVBNSPFBYXGREE-CXWAGAITSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000037851 severe atopic dermatitis Diseases 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000538 tail Anatomy 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【0001】[0001]
【産業上の利用分野】この発明は皮膚外用剤に係り、そ
の目的は皮膚に対する安全性が極めて高く、しかもアト
ピー性皮膚炎やじんましん、或いはニキビ、吹き出物等
の皮膚疾患の症状緩和や増悪の抑制、或いは美肌を目的
として化粧品、薬用化粧品、外用医薬品として安全且つ
効果的に使用することのできる皮膚外用剤を提供するこ
とにある。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for the skin, the purpose of which is to provide extremely high safety to the skin and to alleviate the symptoms of skin diseases such as atopic dermatitis, urticaria, acne and pimples, and to suppress exacerbation. Another object of the present invention is to provide a skin external preparation that can be used safely and effectively as cosmetics, cosmeceuticals, and external medicines for the purpose of beautiful skin.
【0002】[0002]
【従来の技術】古来より”色の白いは七難隠す”と言わ
れているように肌の美白化、美肌化は女性にとっては大
変重要な問題とされている。しかし、社会生活が向上す
るに従ってアトピー性皮膚炎等の皮膚アレルギー症状を
訴える人々が多くなり、特に顔面部に生じた湿疹症状は
化粧年齢の女性を悩ます最大の要因となっている。2. Description of the Related Art As it has been said from ancient times that "white in color hides seven difficulties", skin whitening and skin smoothing are very important issues for women. However, as the social life improves, more and more people complain of skin allergic symptoms such as atopic dermatitis, and the eczema symptom that occurs especially on the face is the biggest factor that afflicts women of makeup age.
【0003】アトピー性皮膚炎は滲出傾向の強い鮮紅色
斑が主に認められる痒みの著しいアレルギー性疾患の一
つである。現代社会には工場の煙や自動車の排気ガス、
暖房が行き届きダニの良好な生育環境となっている居住
空間、さらにはタンパク質や添加物を多量に含んだ欧米
化された食生活、或いは複雑化した人間関係等、アレル
ギーを誘発する要因が多く存在している。一般にアレル
ギーとは、抗原抗体反応が生体に及ぼす影響のうちで病
的の過程を示すものと定義される。具体的にはアレルゲ
ンとの反応でマスト細胞からヒスタミン、ブラディキニ
ン、SRS−Aなどの化学伝達物質が放出され、これら
の物質が周囲の組織を障害して生じる生体反応と解され
ている。従って、前記した化学伝達物質の放出を抑制す
ることによりアレルギー症状の抑制が可能となる。前記
化学伝達物質の一つであるSRS−Aはアラキドン酸代
謝物の一つである5−HETEを前駆体とする物質であ
るから、この5−HETEの産出を抑制することによ
り、アトピー性皮膚炎をはじめ、じんましん等のアレル
ギーを防止することができると考えられている。このよ
うなアトピー性皮膚炎の治療法としては、従来よりヒス
タミン加免疫ブロブリン、強力ミノファーゲンC等を用
いた皮下注射や、副腎皮質ホルモンからなる外用剤が使
用されていた。[0003] Atopic dermatitis is one of the allergic diseases with remarkable itching in which bright red spots with a strong tendency to exude are mainly observed. In modern society, factory smoke, automobile exhaust,
There are many factors that induce allergies, such as living space where heating is perfect and a good environment for the growth of mites, westernized dietary habits containing large amounts of proteins and additives, and complicated human relationships. doing. Generally, allergy is defined as a pathological process among the effects of an antigen-antibody reaction on a living body. Specifically, mast cells release chemical mediators such as histamine, bradykinin, and SRS-A in response to an allergen, and these substances are interpreted as a biological reaction caused by damaging surrounding tissues. Therefore, allergic symptoms can be suppressed by suppressing the release of the above-mentioned chemical messenger. SRS-A, which is one of the chemical mediators, is a substance having 5-HETE, which is one of arachidonic acid metabolites, as a precursor. By suppressing the production of 5-HETE, atopic skin It is believed that allergies such as flame and urticaria can be prevented. As a method for treating such atopic dermatitis, a subcutaneous injection using histamine-added immunoglobulin, strong minophagen C, or the like, or an external preparation consisting of adrenocortical hormone has been conventionally used.
【0004】一方、アレルギー性疾患とは異なるが、ニ
キビ、吹き出物等も思春期の男女に多く認められ、美肌
化を阻害する皮膚疾患の一つである。ニキビは、脂漏性
皮膚疾患に分類され、青年期の男女の顔面、背部など皮
脂線が多く分布している部位に発生し、軽重の差はあっ
ても、思春期男女の約80%に発生が認められている。
ニキビの原因としては、食事や素因等が例示されている
が、特に皮膚表面に存在する黄色ブドウ球菌staphyloco
ccus aureus の作用と関係が深いと解されている。[0004] On the other hand, although different from allergic diseases, acne, pimples and the like are also frequently found in adolescent men and women and are one of the skin diseases that hinder the skin from becoming beautiful. Acne is classified as a seborrheic dermatosis, and it occurs in areas where sebaceous lines are widely distributed, such as the face and back of adolescent men and women. Occurrence has been observed.
The cause of acne is exemplified by diet and predisposition, but especially Staphyloco staphylococcus aureus present on the skin surface
It is believed to be closely related to the action of ccus aureus.
【0005】ニキビの治療法としては、皮膚表面におけ
る黄色ブドウ球菌staphylococcusaureus 等の増殖を防
止する目的でヘキサクロロフェン、トリクロロカルバニ
リド、イルガサン等の抗菌剤を配合した外用剤が主とし
て用いられていた。[0005] As a method for treating acne, an external preparation containing an antibacterial agent such as hexachlorophen, trichlorocarbanilide or irgasan for the purpose of preventing the growth of Staphylococcus aureus or the like on the skin surface has been mainly used.
【0006】[0006]
【発明が解決しようとする課題】しかしながら、前記ア
トピー性皮膚炎の治療に用いられていた抗ヒスタミン等
はいずれも医薬品であるために、処方や治療にあたって
は医師の診断を仰がなければならず、特に皮下注射は効
果が大きい反面、疼痛を伴うので乳幼児の治療には適さ
ないという課題が存在した。さらに副腎皮質ホルモンの
施用は効果が期待できる反面、好ましくない副作用が生
じるという課題が存在し、その使用に危険性が伴うとい
う課題が存在した。また、ニキビの治療や予防等に用い
られていた前記抗菌剤は、その作用が強力であれば、ニ
キビの原因菌以外に皮膚表面上の有用な微生物までも死
滅させてしまったり、或いは顔面に施用するには、これ
らがいずれも薬剤であるために安全性に問題があるとい
う課題が存在した。そこで、業界では皮膚に対する安全
性が極めて高く、乳幼児に対してもその顔面等に安心し
て施用することができるとともに、アトピー性皮膚炎や
蕁麻疹、さらにはニキビ、吹き出物等皮膚疾患の症状の
緩和や増悪の防止等を目的に薬用化粧品、或いは医薬品
として効果的に使用でき、且つこれら皮膚疾患症状以外
にも、美肌化を目的に健常皮膚に化粧品としても好適に
使用することのできる優れた皮膚外用剤の創出が望まれ
ていた。However, since all of the antihistamines and the like used in the treatment of atopic dermatitis are pharmaceuticals, a doctor must be consulted for prescription and treatment. In particular, subcutaneous injection has a large effect, but has a problem that it is not suitable for treating infants because of pain. In addition, while application of corticosteroids can be expected to be effective, there is a problem that undesired side effects occur, and there is a problem that the use thereof involves risks. In addition, the antibacterial agent used for the treatment or prevention of acne, if its action is strong, may kill even useful microorganisms on the skin surface in addition to the causative bacteria of acne, or on the face For application, there was a problem that there was a problem in safety because these are all drugs. Therefore, the safety in the industry is extremely high, and it can be applied to infants and infants with confidence in the face, etc., and also alleviates the symptoms of skin diseases such as atopic dermatitis, urticaria, acne and pimples. An excellent skin that can be effectively used as a cosmeceutical or a pharmaceutical for the purpose of preventing exacerbation or exacerbation, and that can be suitably used as a cosmetic on healthy skin for the purpose of beautifying the skin in addition to these skin disease symptoms. Creation of an external preparation was desired.
【0007】[0007]
【課題を解決するための手段】この発明ではコガネバナ
(Scutellaria baicalensis GEORGI)の粉砕物及び/又
はその抽出物と、粗黒糖から抽出された色素成分とを必
須成分として含有してなることを特徴とする皮膚外用剤
を提供することにより、前記従来の課題を悉く解消す
る。Means for Solving the Problems The present invention is characterized in that it comprises, as essential components, a crushed product of Scutellaria baicalensis GEORGI and / or an extract thereof, and a pigment component extracted from crude brown sugar. By providing an external preparation for skin, the conventional problems described above are completely eliminated.
【0008】[0008]
【発明の構成】以下、この発明の皮膚外用剤の構成につ
いて詳述する。この発明においては、コガネバナ(Scut
ellaria baicalensis GEORGI)の粉砕物及び/又はその
抽出物が必須成分の一つでして用いられる。ここで、コ
ガネバナ(Scutellaria baicalensis GEORGI)とは、中
国、シベリア東部原産のシソ科(Labiatae) の多年草
で、高さは約1m、夏に茎の上部に紫色の花が一方を向
いて穂状に集まって咲く植物で、根部の乾燥物は「オウ
ゴン (Scutellaria Radix)」と呼ばれ、古来より漢方薬
の一種として用いられている。The constitution of the external preparation for skin of the present invention will be described below in detail. In the present invention, Scutellaria (Scut
(ellaria baicalensis GEORGI) and / or an extract thereof are used as one of the essential components. Here, Scutellaria baicalensis GEORGI is a perennial plant belonging to the Labiatae family, which is native to eastern Siberia, China. It is about 1 m in height, and purple flowers face the upper part of the stem in summer to form a spike. It is a plant that blooms, and the dried matter at the root is called "Scutellaria Radix" and has been used as a kind of Chinese medicine since ancient times.
【0009】この発明において用いられるコガネバナ
(Scutellaria baicalensis GEORGI)の部位としては、
葉部、茎部、花部等の地上部、或いは根部等の地下部、
または全草等いずれの部位でも使用することができる
が、より好ましくは茎部の低部位、特に黄色味を帯びた
部位又は根部が、有効成分を多量に含んでいるため望ま
しく使用される。また、用いるコガネバナ(Scutellari
a baicalensis GEORGI)としても、自生する非乾燥状態
のものでも、或いは「オウゴン」と称され、漢方薬の一
つとして市販されているものでもいずれのものでも好適
に使用できる。[0009] The site of Scutellaria baicalensis GEORGI used in the present invention includes:
Above-ground parts such as leaves, stems and flowers, or underground parts such as roots,
Alternatively, any site such as whole plant can be used. More preferably, a low site of the stem, particularly a yellowish site or a root is preferably used because it contains a large amount of the active ingredient. Scutellaria (Scutellari)
a baicalensis GEORGI), a naturally-occurring non-dried one, or a so-called "Ogon", which is commercially available as one of herbal medicines, and any of them can be suitably used.
【0010】このようなコガネバナ(Scutellaria baic
alensis GEORGI)は乾燥、粉砕されて、この発明の必須
成分の一つとして使用される。或いは、その抽出物が必
須成分の一つとして使用される。コガネバナ(Scutella
ria baicalensis GEORGI)の抽出物を用いる場合は、必
要に応じ、乾燥又は粉砕したものを、通常の植物抽出に
用いる適宜な溶媒で抽出して得られるものが特に限定さ
れることなく、好適に使用することができる。[0010] Such Scutellaria baic (Scutellaria baic)
alensis GEORGI) is dried and ground and used as one of the essential components of the present invention. Alternatively, the extract is used as one of the essential components. Scutellaria (Scutella
ria baicalensis GEORGI), if necessary, the dried or ground extract is extracted with an appropriate solvent used for ordinary plant extraction, and is preferably used without particular limitation. can do.
【0011】具体的に抽出溶媒としては、水、メタノー
ル、エタノール、イソプロパノール、イソブタノール、
n−ヘキサノール、メチルアミルアルコール、2−エチ
ルブタノール、n−オクタノール等のアルコール類、エ
チレングリコール、エチレングリコールモノメチルエー
テル、エチレングリコールモノエチルエーテル、プロピ
レンブリコール、プロピレングリコールモノメチルエー
テル、プロピレングリコールモノエチルエーテル、トリ
エチレングリコール、1,3−ブチレングリコール、ヘ
キシレングリコール等の多価アルコール又はその誘導
体、アセトン、メチルアセトン、メチルエチルケトン、
メチルイソブチルケトン、メチル−n−プロピルケトン
等のケトン類、酢酸エチル、酢酸イソプロピル等エステ
ル類、エチルエーテル、イソプロピルエーテル、n−ブ
チルエーテル等のエーテル類などの極性溶媒の一種又は
二種以上の混合溶媒が好適に使用することができるが特
に限定はされない。或いは、石油エーテル、n−ヘキサ
ン、n−ペンタン、n−ブタン、n−オクタン、シクロ
ヘキサン等の脂肪族炭化水素類、四塩化炭素、クロロホ
ルム、ジクロロメタン、トリクロロエチレン、ベンゼ
ン、トルエン等の非極性溶媒の一種又は二種以上の混合
溶媒も好適に使用することができる。さらには前記した
極性溶媒と非極性溶媒との混合溶媒もこの発明において
は特に限定されることなく好適に使用することができ
る。Specifically, the extraction solvent includes water, methanol, ethanol, isopropanol, isobutanol,
alcohols such as n-hexanol, methylamyl alcohol, 2-ethylbutanol, n-octanol, ethylene glycol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, propylene bricol, propylene glycol monomethyl ether, propylene glycol monoethyl ether, Polyhydric alcohols such as triethylene glycol, 1,3-butylene glycol and hexylene glycol or derivatives thereof, acetone, methyl acetone, methyl ethyl ketone,
One or more mixed solvents of polar solvents such as ketones such as methyl isobutyl ketone and methyl-n-propyl ketone, esters such as ethyl acetate and isopropyl acetate, and ethers such as ethyl ether, isopropyl ether and n-butyl ether. Can be preferably used, but there is no particular limitation. Or a kind of non-polar solvent such as petroleum ether, aliphatic hydrocarbons such as n-hexane, n-pentane, n-butane, n-octane, and cyclohexane; carbon tetrachloride, chloroform, dichloromethane, trichloroethylene, benzene, and toluene. Alternatively, a mixed solvent of two or more types can also be suitably used. Further, the above-mentioned mixed solvent of a polar solvent and a non-polar solvent can be suitably used in the present invention without any particular limitation.
【0012】コガネバナ(Scutellaria baicalensis GE
ORGI)の抽出物について、より具体的に詳述すると、茎
部の低部位、特に黄色味を帯びた部位及び根部には、こ
の発明の有効成分の一つとされるフラボノイド化合物が
多数含有されている。すなわち、次式1(化1)で示さ
れるバイカリン、次式2(化2)で示されるバイカレイ
ン、次式3(化3)で示されるクリシン、次式4(化
4)で示されるオーゴニン、次式5(化5)で示される
オーゴニン−7−O−D−グルクロニド、次式6(化
6)で示されるスカルカプフラボン、次式7(化7)で
示される2',5,5',7−テトラヒドロキシ−6' ,
8−ジメトキシフラボン、次式8(化8)で示される
(2S)−2',5,6' ,7−テトラヒドロキシフラボ
ン、次式9(化9)で示される(2R,3R)−2',
3,5,6' ,7−ペンタヒドロキシフラボンなどのフ
ラボノイド化合物が茎の低部位及び根部に多量に含有さ
れており、この発明においては前記フラボノイド化合物
のうちの一種又は二種以上を精製、単離して必須成分の
一つとして使用することもできる。Scutellaria baicalensis GE
More specifically, the extract of (ORGI) is described in detail.The low part of the stem, particularly the yellowish part and the root, contain a large number of flavonoid compounds which are one of the active ingredients of the present invention. I have. That is, baicalin represented by the following formula (1), baicalein represented by the following formula (2), chrysin represented by the following formula (3), agonine represented by the following formula (4): Orgonin-7-OD-glucuronide represented by the following formula 5 (formula 5), scalcapflavone represented by the following formula 6 (formula 6), 2 ′, 5,5 represented by the following formula 7 (formula 7) ', 7-tetrahydroxy-6',
8-Dimethoxyflavone, (2S) -2 ′, 5,6 ′, 7-tetrahydroxyflavone represented by the following formula 8 (Chemical formula 8), (2R, 3R) -2 represented by the following formula 9 (Chemical formula 9) ',
Flavonoid compounds such as 3,5,6 ', 7-pentahydroxyflavone are contained in large amounts in the low and root portions of stems. In the present invention, one or more of the above flavonoid compounds are purified, and It can be used separately as one of the essential components.
【0013】[0013]
【化1】 Embedded image
【化2】 Embedded image
【化3】 Embedded image
【化4】 Embedded image
【化5】 Embedded image
【化6】 Embedded image
【化7】 Embedded image
【化8】 Embedded image
【化9】 Embedded image
【0014】また、この発明においては前記コガネバナ
(Scutellaria baicalensis GEORGI)の粉砕物及び/又
はその抽出物とともに粗黒糖から抽出された色素成分も
必須成分として使用される。ここで、色素成分とは、シ
ョ糖の未精製品(黒砂糖)から得られる黒色色素成分
(例えばコクトオリゴ(商品名、(株)大阪薬品研究所
製)のことを指す。この色素成分を得る方法としては、
例えば次の方法が例示される。すなわち、原料となる粗
黒糖を適当量の水に溶解し、これを吸着剤に接触させて
色素成分を吸着させ、水洗して糖分を充分に除去した
後、吸着させた色素成分を溶剤により溶離させることに
より抽出・分離する。通常、この操作は吸着剤のカラム
を用い、水及び溶剤を流下させて行なう。この場合、用
いられる吸着剤としては、非極性のポリスチレン系吸着
樹脂、例えばアンバーライトXAD−1、アンバーライ
トXAD−2(商品名、ローム・アンド・ハース社製)
及びセルバクロムXAD−2(商品名、セルバ社製)が
好適である。尚、収率の点からはセルバクロムXAD−
2が好ましいが特に限定はされない。この段階で得た粗
黒色色素成分もこの発明においては必須成分の一つとし
て好適に使用できる。すなわち、流出液を減圧下で濃縮
し、流エキス、軟エキス、乾燥エキスとして用いること
ができる。In the present invention, a pigment component extracted from crude brown sugar is used as an essential component together with the ground material of Scutellaria baicalensis GEORGI and / or an extract thereof. Here, the pigment component refers to a black pigment component (for example, Coctoligo (trade name, manufactured by Osaka Pharmaceutical Laboratory Co., Ltd.)) obtained from an unrefined product of sucrose (brown sugar). As a method,
For example, the following method is exemplified. That is, the crude brown sugar as a raw material is dissolved in an appropriate amount of water, and this is brought into contact with an adsorbent to adsorb the dye component, washed with water to sufficiently remove sugar, and the adsorbed dye component is eluted with a solvent. Extraction and separation by Usually, this operation is carried out using a column of an adsorbent and flowing down water and a solvent. In this case, the adsorbent used is a non-polar polystyrene-based adsorption resin, for example, Amberlite XAD-1, Amberlite XAD-2 (trade name, manufactured by Rohm and Haas)
And Selvachrome XAD-2 (trade name, manufactured by Selva) are preferred. In addition, in terms of yield, Selvachrome XAD-
2 is preferred, but not particularly limited. The crude black dye component obtained at this stage can also be suitably used as one of the essential components in the present invention. That is, the effluent is concentrated under reduced pressure, and can be used as a flow extract, a soft extract, and a dry extract.
【0015】尚、吸着剤の使用量は含有色素成分量の8
0〜800倍(重量比)、より好ましくは50〜200
倍(重量比)とするのが望ましい。また、吸着した色素
成分を溶離させるに際して、溶離前に水洗して洗液の甘
味が全くなくなるまで充分に糖分を除去させることが好
ましい。色素成分の溶離は濃度20%以上の低級アルコ
ール、例えばメタノール又はエタノールで行なうのが好
適である。実際には、まず20〜30%の低級アルコー
ルで溶離を行い、流下液の着色が殆ど認められなくなっ
た後、95〜99%の高濃度低級アルコールでさらに溶
離させるのが好ましい。この理由は、低濃度低級アルコ
ールのみで溶離を行なうと色素成分の収率が低下し、好
ましくないからである。このようにして得た溶離液を蒸
発乾固して、この発明の必須成分の一つである粗黒糖の
色素成分を得ることができる。尚、糖分の除去が不完全
で、溶離液に甘味が残存する場合には、その蒸発残留物
を純エタノール等の純低級アルコールに混合し、不溶の
糖分を濾別し、除去し、濾液から色素成分を再結晶させ
て得ることが純度の高い色素成分を得るにあたって好ま
しい。The amount of the adsorbent used is 8 times the amount of the dye component contained.
0 to 800 times (weight ratio), more preferably 50 to 200 times
It is desirable to make it twice (weight ratio). When eluting the adsorbed dye component, it is preferable to wash with water before elution to sufficiently remove sugars until the washing liquid has no sweetness. The elution of the dye component is preferably performed with a lower alcohol having a concentration of 20% or more, for example, methanol or ethanol. In practice, it is preferable to elute first with 20 to 30% of lower alcohol, and then to elute with 95 to 99% of higher concentration lower alcohol after coloring of the flowing liquid is hardly observed. The reason for this is that elution with only low-concentration lower alcohol reduces the yield of the dye component, which is not preferable. The eluate thus obtained can be evaporated to dryness to obtain a crude brown sugar dye component, which is one of the essential components of the present invention. If the removal of sugar is incomplete and the sweetness remains in the eluate, the evaporation residue is mixed with pure lower alcohol such as pure ethanol, the insoluble sugar is filtered off and removed, and the filtrate is removed from the filtrate. It is preferable to obtain the dye component with high purity by recrystallizing the dye component.
【0016】また、この発明の粗黒糖から抽出される色
素成分を得る方法として、前記した方法以外に、粗黒糖
をメタノール、純エタノール等の純低級アルコールに直
接冷浸又は温浸し、不溶の糖分を濾過等の方法により除
去したのち、残液を蒸発乾固して色素成分を得る方法も
使用することができる。As a method for obtaining a pigment component extracted from crude brown sugar of the present invention, in addition to the above-described method, crude brown sugar is directly cold-immersed or digested in a pure lower alcohol such as methanol or pure ethanol to obtain an insoluble sugar content. May be removed by filtration or the like, and then the remaining liquid is evaporated to dryness to obtain a pigment component.
【0017】以上のような方法により抽出、分離された
粗黒糖の色素成分は、そのままこの発明の必須成分とし
て使用することができる。この色素成分には、様々な成
分が含有されているが、主としてフェニルグルコース類
等のオリゴ糖が主成分として含有されている。この具体
例としては、例えば次式10(化10)で示される2,
5−ジメトキシフェニル−O−グルコース及び次式11
(化11)で示される2,4,5−トリメトキシフェニ
ル−O−グルコース、次式12(化12)で示される
3,4−ジメトキシフェニル−O−D−グルコース、次
式13(化13)で示される3,4,6−トリメトキシ
フェニル−O−D−グルコース等が代表例として例示さ
れる。The pigment component of crude brown sugar extracted and separated by the above method can be used as an essential component of the present invention as it is. Although various components are contained in the pigment component, oligosaccharides such as phenylglucose are mainly contained as main components. As a specific example, for example,
5-dimethoxyphenyl-O-glucose and the following formula 11
2,4,5-trimethoxyphenyl-O-glucose represented by the following formula (12), 3,4-dimethoxyphenyl-OD-glucose represented by the following formula (12), and the following formula (13) 3,4,6-trimethoxyphenyl-OD-glucose or the like represented by the formula (1).
【0018】[0018]
【化10】 Embedded image
【化11】 Embedded image
【化12】 Embedded image
【化13】 Embedded image
【0019】以上のようなオリゴ糖を主成分とする粗黒
糖の色素成分は、原料粗黒糖から0.05〜0.3重量
%程度の収率で得ることができ、淡褐色の吸湿性の粉末
で、僅かに焦臭があり、味は僅かに苦い粉末である。The pigment component of crude brown sugar containing oligosaccharide as a main component as described above can be obtained from the raw crude sugar in a yield of about 0.05 to 0.3% by weight, and has a light brown hygroscopicity. It is a powder with a slightly burning odor and a slightly bitter taste.
【0020】この発明においては、前記したコガネバナ
(Scutellaria baicalensis GEORGI)の粉砕物及び/又
はその抽出物と、粗黒糖から抽出された色素成分とを必
須成分とするが、ここでこれら必須成分の配合比率とし
ては、それぞれ皮膚外用剤全量中0.01〜0.1%、
より好ましくは0.02〜0.05%程度とされるのが
望ましい。また、コガネバナ(Scutellaria baicalensi
s GEORGI)の粉砕物及び/又はその抽出物と、粗黒糖か
ら抽出された色素成分との比率は3:7〜7:3、より
好ましくは5:5程度とされるのが望ましい。この理由
は、コガネバナ(Scutellaria baicalensis GEORGI)の
粉砕物及び/又はその抽出物に対して、粗黒糖から抽出
された色素成分の配合が3/10未満であると、この発
明の目的とする皮膚疾患に対する極めて優れた効果を発
現することができず、一方、粗黒糖から抽出された色素
成分の配合が、コガネバナ(Scutellaria baicalensis
GEORGI)の粉砕物及び/又はその抽出物に対して、7/
10を超えて配合されてもその配合例に比例した効果を
得ることができず、いずれの場合も好ましくないからで
ある。According to the present invention, the above-mentioned ground material of Scutellaria baicalensis GEORGI and / or an extract thereof and a pigment component extracted from crude brown sugar are essential components. The ratio is 0.01 to 0.1% of the total amount of the external preparation for skin,
More preferably, it is desirably about 0.02 to 0.05%. Also, Scutellaria baicalensi
s GEORGI) and the ratio of the pigment component extracted from crude brown sugar to the pigment component extracted from crude brown sugar are desirably about 3: 7 to 7: 3, more preferably about 5: 5. The reason for this is that if the amount of the pigment component extracted from crude brown sugar is less than 3/10 with respect to the ground material of Scutellaria baicalensis GEORGI and / or its extract, the skin disease targeted by the present invention Is not able to exhibit an extremely good effect on cornflower, while the combination of pigment components extracted from crude brown sugar makes it possible to use Scutellaria baicalensis
GEORGI) and / or its extract
This is because, even if the amount is more than 10, the effect proportional to the compounding example cannot be obtained, and in any case, it is not preferable.
【0021】この発明において、前記した必須成分は、
そのまま皮膚外用剤として使用することもできるが、よ
り好ましくは公知の賦形剤や希釈剤、或いは他の任意の
配合材料とともに混合して顆粒、エマルション、溶液、
懸濁液などの剤形に調製して使用される。この発明にお
いて、最終形態である皮膚外用剤としては、美容を目的
として健常皮膚に施用する化粧品であっても、或いはニ
キビ、吹き出物等の症状の悪化の防止や症状の改善、さ
らにはニキビ痕の残った肌の美肌化等を目的とした薬用
化粧品(医薬部外品)であっても、さらにはアトピー性
皮膚炎やじんましん等アレルギー性皮膚炎の治療を目的
とした医薬品であってもよく、いずれの形態も任意に採
用することができる。しかも、これら剤形に調製する
際、従来より公知のイオウ製剤やサルチル酸、レゾルシ
ン等の角質溶解剤や、ヘキサクロロフェン、トリクロロ
カルバニリド、イルガサン、クロルヘキシジン等の抗菌
剤等を、この発明の効果を損なわない範囲で適宜併用し
て用いることもできる。さらに、皮膚保湿剤として公知
のヒアルロン酸や加水分解コラーゲン、さらには美白剤
として公知のビタミンC又はその誘導体等も適宜任意に
併用することができる。In the present invention, the essential components described above include:
It can be used as it is as a skin external preparation, but more preferably mixed with known excipients and diluents, or any other compounding materials, granules, emulsions, solutions,
It is prepared and used in the form of a suspension or the like. In the present invention, the final form of the skin external preparation may be a cosmetic applied to healthy skin for the purpose of cosmetics, or acne, prevention of deterioration of symptoms such as pimples, improvement of symptoms, and even acne scars. It may be a medicated cosmetic (quasi-drug) for the purpose of beautifying the remaining skin, or a pharmaceutical for the treatment of allergic dermatitis such as atopic dermatitis and urticaria. Either form can be arbitrarily adopted. Moreover, when prepared into these dosage forms, conventionally known sulfur preparations, keratolytic agents such as salicylic acid and resorcin, and antibacterial agents such as hexachlorophene, trichlorocarbanilide, irgasan, chlorhexidine, and the like can be used. Can be used in combination as appropriate within a range that does not impair. Further, hyaluronic acid and hydrolyzed collagen known as skin moisturizing agents, and vitamin C or a derivative thereof known as a whitening agent can be optionally used in combination.
【0022】具体的に化粧品としては、ローション、乳
液、クレンジングクリーム、マッサージクリーム、エモ
リエントクリーム等クリーム類、パック類等の基本化粧
品、或いはファンデーション、ほほ紅等メークアップ化
粧品等が好適な実施例として例示される。また薬用化粧
品としては、石けん、洗顔クリーム、ニキビの改善・予
防を目的としたローションや乳液、パック、ボディロー
ション、入浴剤等が、さらに医薬品としては軟膏、クリ
ーム等が好適な実施例として例示することができるが、
この発明において特に限定はされない。Specific examples of preferred cosmetics include basic cosmetics such as lotions, emulsions, cleansing creams, creams such as massage creams and emollient creams, packs, and makeup cosmetics such as foundations and blushers. Is done. Examples of suitable medicated cosmetics include soaps, facial cleansers, lotions and emulsions for the purpose of improving and preventing acne, packs, body lotions, bath salts, and the like. Further, as pharmaceuticals, ointments, creams, and the like are exemplified as preferred examples. Can be
There is no particular limitation in the present invention.
【0023】このような皮膚外用剤においては、その製
造工程の任意の段階で、前記コガネバナ(Scutellaria
baicalensis GEORGI)の粉砕物及び/又はその抽出物と
粗黒糖から抽出された色素成分とを任意の量配合すれば
よい。In such an external preparation for skin, the Scutellaria (Scutellaria) is used at any stage of the manufacturing process.
Any desired amount of the pulverized product of Bacillus baicalensis GEORGI) and / or its extract and the pigment component extracted from crude brown sugar may be blended.
【0024】[0024]
【実施例】以下、この発明に係る皮膚外用剤の効果を実
施例を挙げて説明する。但し、この発明は以下の実施例
により何ら限定はされない。EXAMPLES The effects of the external preparation for skin according to the present invention will be described below with reference to examples. However, the present invention is not limited at all by the following examples.
【0025】(1)コガネバナ(Scutellaria baicalen
sis GEORGI)粉砕物の調製サンプル(A) コガネバナ(Scutellaria baicalensis GEORGI)全草の
非乾燥物50gを細切りし、この細切物をメタノールで
60℃にて1〜2時間加熱下で抽出し、この抽出操作を
4回繰り返した後、得られた抽出物を濾過し、濾液をさ
らに減圧濃縮して乾固して、約10gの抽出物を得た。サンプル(B) コガネバナ(Scutellaria baicalensis GEORGI)茎部と
根部とを乾燥、粉砕した後、メタノールで60℃にて1
〜2時間加熱下で抽出し、この抽出操作を4回繰り返し
た後、得られた抽出物を濾過し、濾液をさらに減圧濃縮
して乾固物とした。サンプル(C) 前記サンプル(C)で得られた抽出物をカラムクロマト
グラフィーにて4つのフラクションに分離した(C−
1,C−2,C−3,C−4)。各フラクションをそれ
ぞれ減圧濃縮して乾固物とした。(尚、各フラクション
について高速液体クロマトグラフィーを用いて同定した
ところ、C−1はバイカリン、C−2はオーゴニン、C
−3はオーゴニン7−O−グルクロニド、C−4はバイ
カレインであることが同定された。)サンプル(D) コガネバナ(Scutellaria baicalensis GEORGI)根部を
乾燥した後、粉砕して粉砕物とした。(1) Scutellaria baicalen
Preparation of crushed sis GEORGI sample (A) 50 g of non-dried whole plant of Scutellaria baicalensis GEORGI was cut into small pieces, and the cut pieces were extracted with methanol at 60 ° C. for 1 to 2 hours under heating. After repeating the extraction operation four times, the obtained extract was filtered, and the filtrate was further concentrated under reduced pressure and dried to obtain about 10 g of the extract. Sample (B) After drying and pulverizing the stem and root of Scutellaria baicalensis GEORGI, methanol was added at 60 ° C for 1 hour.
Extraction was performed for 2 hours with heating, and this extraction operation was repeated four times. Then, the obtained extract was filtered, and the filtrate was further concentrated under reduced pressure to dryness. Sample (C) The extract obtained in Sample (C) was separated into four fractions by column chromatography (C-
1, C-2, C-3, C-4). Each fraction was concentrated under reduced pressure to dryness. (When each fraction was identified using high performance liquid chromatography, C-1 was baicalin, C-2 was agonine, C
-3 was identified as agonine 7-O-glucuronide, and C-4 was identified as baicalein. ) Sample (D) The root of Scutellaria baicalensis GEORGI was dried and then pulverized to a pulverized product.
【0026】(2)粗黒糖から抽出した色素成分の調製 サンプル(E) 沖縄産黒砂糖5Kgを水25リットルに溶解し、ポリスチレ
ン系樹脂(アンバーライトXAD−2,2500g)を水1
リットルに分散させて充填した内径8cmのカラムに注入
し、20ml/分の速度で流下させ黒砂糖の色素成分を吸着
させた。次に水を流下させ甘味の全くなくなるまで水洗
して充分に糖分を除き、95%メタノールを注入し、10ml
/分の速度で流下させ吸着剤から色素を溶離させた。流
下液に着色がなくなるまで流下を続け流出液を混合し、
60℃以下で減圧蒸発乾固し、残留物を60℃以下で減圧蒸
発乾固し、甘味の全くない褐色の粉末色素成分8g を得
た。サンプル(F) 沖縄産黒砂糖5Kgを水25リットルに溶解し、ポリスチレ
ン系樹脂(セルバクロムXAD−2,300g)を水1リッ
トルに分散させて充填した内径8cmのカラムに注入し、
20ml/分の速度で流下させ黒砂糖の色素成分を吸着させ
た。次に水を流下させ甘味の全くなくなるまで水洗して
充分に糖分を除き、流下液に甘味が全くなくなってから
20%メタノールを注入し、10ml/分の速度で流下させ吸
着剤から色素を溶離させた。流下液に着色がほとんど認
められなくなった時点で、溶離液を95%メタノールに代
え、流下液に着色が全くなくなるまで流下を続けた。両
流下溶離液を混合し、60℃以下で減圧蒸発乾固し、褐色
残留物16g を得た。このものを2リットルの純エタノー
ルに加熱して溶かし、冷却後、析出した濁り物質を濾別
し、60℃以下で減圧蒸発乾固し、その残留物を60℃以下
で乾燥して甘味の全くない褐色の粉末色素成分15g を得
た。 (2) Preparation of Pigment Component Extracted from Crude Brown Sugar (E) 5 kg of brown sugar from Okinawa is dissolved in 25 liters of water, and a polystyrene resin (Amberlite XAD-2, 2500 g) is added to water 1
The mixture was poured into a column having an inner diameter of 8 cm, which was dispersed and packed in liter, and allowed to flow down at a rate of 20 ml / min to adsorb the pigment component of brown sugar. Next, let the water flow down and wash with water until the sweetness has completely disappeared, sufficiently remove the sugar, inject 95% methanol, and add 10 ml
The dye was eluted from the adsorbent by flowing down at a rate of 1 / min. Continue flowing down until the flowing liquid is no longer colored, mix the effluent,
The residue was evaporated to dryness under reduced pressure at 60 ° C. or less, and the residue was evaporated to dryness at 60 ° C. or less to obtain 8 g of a brown powder pigment component having no sweetness. Sample (F) 5 kg of brown sugar produced in Okinawa is dissolved in 25 liters of water, and polystyrene resin (Selvachrome XAD-2, 300 g) is dispersed in 1 liter of water and injected into a column having an inner diameter of 8 cm and filled.
It was allowed to flow down at a rate of 20 ml / min to adsorb the pigment component of brown sugar. Next, let the water flow down and wash with water until the sweetness is completely gone to remove sugar sufficiently.
The dye was eluted from the adsorbent by injecting 20% methanol and flowing down at a rate of 10 ml / min. When little color was observed in the flowing solution, the eluent was replaced with 95% methanol, and the flow was continued until the flowing solution was completely free of color. The eluates were mixed under both flows, and evaporated to dryness under reduced pressure at 60 ° C. or lower to obtain 16 g of a brown residue. This is heated and dissolved in 2 liters of pure ethanol, and after cooling, the precipitated turbid substance is separated by filtration, evaporated to dryness under reduced pressure at 60 ° C or less, and the residue is dried at 60 ° C or less to obtain a completely sweet product. 15 g of a brown powdery pigment component was obtained.
【0027】(実施例1〜5及び比較例1〜3) (実施例1)薬用ローション 重量% コガネバナ抽出物〔サンプル(B)〕 0.02 粗糖色素成分〔サンプル(E)〕 0.02 d−カンフル 0.02 l−メントール 0.05 1,3−ブチレングリコール 5.0 エタノール 15.0 香 料 適 量 精 製 水 残 部 100.0 (実施例2)薬用クレンジングクリーム 重量% コガネバナ抽出物〔サンプル(A)〕 0.02 粗糖色素成分〔サンプル(F)〕 0.03 軽質流動パラフィン 35.0 ミツロウ 8.0 パルミチン酸セチル 3.0 ラノリン 1.0 セスキオレイン酸ソルビタン 2.0 ポリオキシエチレン(20)ソルビットミツロウ 4.5 防腐剤・酸化防止剤 適 量 70%ソルビトール 4.0 香 料 適 量 精 製 水 残 部 100.0(Examples 1 to 5 and Comparative Examples 1 to 3) (Example 1) Medicinal lotion weight% Scutellaria extract [Sample (B)] 0.02 Crude sugar pigment component [Sample (E)] 0.02 d - camphor 0.02 l-menthol 0.05 1,3-butylene glycol 5.0 ethanol 15.0 perfume qs refining water balance section 100.0 (example 2) medicinal cleansing cream wt% Scutellaria extract [ Sample (A)] 0.02 Crude sugar pigment component [Sample (F)] 0.03 Light liquid paraffin 35.0 Beeswax 8.0 Cetyl palmitate 3.0 Lanolin 1.0 Sorbitan sesquioleate 2.0 Polyoxyethylene (20) sorbit beeswax 4.5 preservative antioxidant qs 70% sorbitol 4.0 perfume qs refining water balance section 100.0
【0028】(実施例3)薬用パック 重量% コガネバナ粉砕物 0.04 〔サンプル(C)にて得られたバイカレインと オーゴニンとの1:1混合物〕 粗糖色素成分〔サンプル(E)〕 0.02 ポリビニルアルコール 14.0 酢酸ビニル樹脂エマルション 10.0 エチルアルコール 7.0 カオリン 10.0 グリセロール 1.0 パラベン 0.01 香 料 適 量 精製水 残 部 100.0 (実施例4)薬用ボディシャンプー 重量% コガネバナ粉砕物 0.06 〔サンプル(C)にて得られたバイカレインと オーゴニン7−O−グルクロニドとの1:1混合物〕 粗糖色素成分〔サンプル(F)〕 0.05 ラウリル硫酸ナトリウム 10.0 ラウリルスルホコハク酸ナトリウム 20.0 ラウリルジエタノールアミド 4.0 加水分解コラーゲン 1.0 ジステアリン酸エチレングリコール 1.0 エデト酸四ナトリウム四水塩 0.1 アラントイン 0.01 塩化リゾチーム 0.01 香 料 適 量 精製水 残 部 100.0(Example 3) Medicinal pack weight% Cranberry crushed matter 0.04 [1: 1 mixture of baicalein and agonine obtained in sample (C)] Crude sugar pigment component [sample (E)] 0.02 Polyvinyl alcohol 14.0 Vinyl acetate resin emulsion 10.0 Ethyl alcohol 7.0 Kaolin 10.0 Glycerol 1.0 Paraben 0.01 Perfume Appropriate amount Purified water Balance 100.0 (Example 4) Medicinal body shampoo weight% Pulverized Scutellaria 0.06 [1: 1 mixture of baicalein and agonine 7-O-glucuronide obtained in sample (C)] Crude sugar pigment component [sample (F)] 0.05 Sodium lauryl sulfate 10.0 lauryl Sodium sulfosuccinate 20.0 Lauryl diethanolamide 4.0 Hydrolysis collar Down 1.0 Ethylene glycol distearate 1.0 edetate tetrasodium tetrahydrate 0.1 allantoin 0.01 Lysozyme chloride 0.01 Perfume qs Purified water balance section 100.0
【0029】(実施例5)軟 膏 重量% コガネバナ抽出物〔サンプル(D)〕 0.08 粗糖色素成分〔サンプル(E)〕 0.05 グリセリン 10.0 ミツロウ 20.0 オリーブ油 4.0 香 料 適 量 100.0(Example 5) Ointment weight% Scutellaria extract [Sample (D)] 0.08 Crude sugar pigment component [Sample (E)] 0.05 Glycerin 10.0 Beeswax 20.0 Olive oil 4.0 Flavor Appropriate amount 100.0
【0030】(比較例1)薬用ローション 重量% コガネバナ抽出物〔サンプル(B)〕 0.02 d−カンフル 0.02 l−メントール 0.05 1,3−ブチレングリコール 5.0 エタノール 15.0 香 料 適 量 精 製 水 残 部 100.0 (比較例2)薬用ローション 重量% 粗糖色素成分〔サンプル(E)〕 0.02 d−カンフル 0.02 l−メントール 0.05 1,3−ブチレングリコール 5.0 エタノール 15.0 香 料 適 量 精 製 水 残 部 100.0 (比較例3)薬用ローション 重量% d−カンフル 0.02 l−メントール 0.05 1,3−ブチレングリコール 5.0 エタノール 15.0 香 料 適 量 精 製 水 残 部 100.0Comparative Example 1 Medicinal lotion weight% Scutellaria extract [sample (B)] 0.02 d-camphor 0.02 1-menthol 0.05 1,3-butylene glycol 5.0 ethanol 15.0 incense charge qs refining water balance section 100.0 (Comparative example 2) medicinal lotion wt% raw sugar dye component sAMPLE (E)] 0.02 d-camphor 0.02 l-menthol 0.05 1,3-butylene glycol 5.0 ethanol 15.0 perfume qs refining water balance section 100.0 (Comparative example 3) medicinal lotion wt% d- camphor 0.02 l-menthol 0.05 1,3-butylene glycol 5.0 ethanol 15.0 perfume qs refining water balance section 100.0
【0031】[0031]
【試験例】以下、試験例を挙げてこの発明に係る皮膚外
用剤の効果を一層明らかなものとする。Test Examples The effects of the external preparation for skin according to the present invention will be further clarified with reference to test examples.
【0032】(試験例1)前記実施例1及び比較例1〜
3で調製された薬用ローションを、(A)ニキビ症状の
ひどい13〜17才の男女20名、(B)アトピー性皮
膚炎のひどい7〜12才の男女小児20名に、それぞれ
朝夕1日2回、各薬用ローションを継続して2週間、症
状のひどい部位に塗布した。各薬用ローション塗布2週
間後の施用部位の症状の改善状態を目視により評価し
た。症状がほとんど消失してしまったものを◎、症状の
改善が認められたものを〇、症状に変化が認められなか
ったものを×とした。この結果を表1に示す。Test Example 1 Example 1 and Comparative Examples 1 to
The medicated lotion prepared in (3) was administered to (A) 20 male and female children aged 13 to 17 years with severe acne symptoms, and (B) 20 male and female children aged 7 to 12 years with severe atopic dermatitis. Each time, each medicated lotion was continuously applied for 2 weeks to the severely affected area. Two weeks after the application of each medicated lotion, the state of improvement of the symptoms at the application site was visually evaluated. ◎ indicates that the symptom almost disappeared, 〇 indicates improvement of the symptom, and × indicates no change in the symptom. Table 1 shows the results.
【0033】[0033]
【表1】 [Table 1]
【0034】(実施例6〜10及び比較例4〜7) (実施例6)前記サンプル(A)にて得られたコガネバ
ナ全草のメタノール抽出物と、サンプル(E)にて得ら
れた粗糖の色素成分とを等量混合した。 (実施例7)前記サンプル(B)にて得られたコガネバ
ナ茎部及び根部のメタノール抽出物と、サンプル(F)
にて得られた粗糖の色素成分とを等量混合した。 (実施例8)前記サンプル(C)にて得られたバイカレ
イン及びオーゴニンとの等量混合物と、サンプル(E)
にて得られた粗糖の色素成と等量を混合して混合物とし
た。 (実施例9)前記サンプル(C)にて得られたバイカレ
イン及びオーゴニン7−O−グルクロニドとサンプル
(F)にて得られた粗糖の色素成分とを等量混合して混
合物とした。 (実施例10)前記サンプル(D)にて得られたコガネ
バナ根部の粉砕物と、サンプル(E)にて得られた粗糖
の色素成分とを等量混合して混合物とした。(Examples 6 to 10 and Comparative Examples 4 to 7) (Example 6) A methanol extract of whole Scutellaria obtained from the sample (A) and the crude sugar obtained from the sample (E) And an equal amount of the above dye component. (Example 7) The methanol extract of the Scutellaria stalk and root obtained in the sample (B) and the sample (F)
And an equal amount of the pigment component of the crude sugar obtained in the above. (Example 8) Equivalent mixture of baicalein and agonine obtained in sample (C) and sample (E)
The crude sugar obtained in the above was mixed with an equivalent amount of the pigment to obtain a mixture. (Example 9) Equivalent amounts of the baicalein and agonine 7-O-glucuronide obtained in the sample (C) and the pigment component of the crude sugar obtained in the sample (F) were mixed to form a mixture. (Example 10) An equal amount of the ground component of Scutellaria root obtained in the sample (D) and the pigment component of the crude sugar obtained in the sample (E) were mixed to obtain a mixture.
【0035】(比較例4)前記サンプル(A)にて得ら
れたコガネバナ全草のメタノール抽出物のみを用いた。 (比較例5)前記サンプル(B)にて得られたコガネバ
ナ茎部及び根部のメタノール抽出物のみを用いた。 (比較例6)前記サンプル(D)にて得られたコガネバ
ナ根部の乾燥粉砕物のみを用いた。 (比較例7)前記サンプル(E)にて得られた粗糖の色
素成分のみを用いた。(Comparative Example 4) Only the methanol extract of whole Aspergillus oryzae obtained in the sample (A) was used. (Comparative Example 5) Only the methanol extract of Scutellaria stalk and root obtained in the sample (B) was used. (Comparative Example 6) Only the dried and pulverized material of Scutellaria root obtained in the sample (D) was used. (Comparative Example 7) Only the pigment component of the crude sugar obtained in the sample (E) was used.
【0036】(試験例2)黄色ブドウ球菌に対する抗菌活性 前記実施例6〜10及び比較例4〜7の各試料をそれぞ
れエタノールで10倍量に溶解し、そのうちの0.05
mlを内径8mmの濾紙ディスクに含浸させ、被験菌と
して黄色ブドウ球菌staphylococcus aureus 269Pを接種
分散させた寒天平板(ハートインヒュージョン寒天培
地、日水製薬(株)製)上に接着し、35℃で24時間
培養した。培養終了後、濾紙の周囲の発育阻止円の大き
さを算出した。この結果を表2に示す。(Test Example 2) Antibacterial activity against Staphylococcus aureus Each of the samples of Examples 6 to 10 and Comparative Examples 4 to 7 was dissolved in ethanol to a 10-fold amount, and 0.05 of them was dissolved.
of the sample was impregnated into a filter paper disk having an inner diameter of 8 mm, adhered onto an agar plate (Heart In Fusion Agar Medium, manufactured by Nissui Pharmaceutical Co., Ltd.) inoculated and dispersed with Staphylococcus aureus 269P as a test bacterium, and heated at 35 ° C. Cultured for 24 hours. After completion of the culture, the size of the growth inhibition circle around the filter paper was calculated. Table 2 shows the results.
【0037】[0037]
【表2】 [Table 2]
【0038】(試験例3)前記実施例6〜10及び比較
例4〜7で得られた各試料の5−HETEの産出阻害活
性を試験した。ウイスター系雄ラットを使用し、このラ
ット腹腔内多核白血球をHEPS−生食緩衝液(pH
7.4)で洗浄し、同緩衝液に懸濁、超音波処理を行な
ったものをアラキドン酸代謝の酵素液として用いた。こ
の血小板ホモジネイトと前記実施例及び比較例とのサン
プルをそれぞれ表3に示す濃度に調製し、37℃で5分
間、保温した。その後、〔1-14 C〕アラキドン酸
(0.05μCi)を加え、5分間インキュベイトし
た。終了後、反応をギ酸で止め(pH3)アラキドン酸
代謝物を酢酸エチルで抽出し、シリカゲル薄層クロマト
グラフィー(TLC)で分離して定量した(展開液;石
油エーテル:エーテル:酢酸=50:50:1、v/
v、TLCはメルク5748)。放射活性物質はオート
ラジオグラフィで検出し、そのスポットを切取り、放射
活性体を液体シンチレーションカウンターで定量した。
(尚、実施例及び比較例のサンプルを使用しなかったも
のを対照例とした。) この結果を表3に示す。(尚、表3中に示すHHT(1
2−ハイドロキシヘプタデカトリエン酸)はシクロオキ
シゲナーゼを経て代謝される5−ハイドロキシエイコサ
テトラエン酸(5−HETE)である。Test Example 3 The samples obtained in Examples 6 to 10 and Comparative Examples 4 to 7 were tested for 5-HETE production inhibitory activity. Using Wistar male rats, the rat intraperitoneal polynuclear leukocytes were converted to HEPS-saline buffer (pH
The mixture was washed in 7.4), suspended in the same buffer solution and subjected to ultrasonic treatment, and used as an enzyme solution for arachidonic acid metabolism. The samples of the platelet homogenate and the above Examples and Comparative Examples were each adjusted to the concentrations shown in Table 3 and kept at 37 ° C. for 5 minutes. Thereafter, [1 -14 C] arachidonic acid (0.05 μCi) was added, and the mixture was incubated for 5 minutes. After completion, the reaction was stopped with formic acid (pH 3), and arachidonic acid metabolite was extracted with ethyl acetate and separated and quantified by silica gel thin-layer chromatography (TLC) (developing solution; petroleum ether: ether: acetic acid = 50: 50). : 1, v /
v, TLC is Merck 5748). The radioactive substance was detected by autoradiography, the spot was cut out, and the radioactive substance was quantified with a liquid scintillation counter.
(It should be noted that those in which the samples of Examples and Comparative Examples were not used were used as control examples.) The results are shown in Table 3. (Note that HHT (1
2-Hydroxyheptadecatrienoic acid) is 5-hydroxyeicosatetraenoic acid (5-HETE) that is metabolized via cyclooxygenase.
【0039】[0039]
【表3】 [Table 3]
【0040】表1の結果から明らかな如く、コガネバナ
の抽出物のみを配合した薬用ローション(比較例1)で
は、アトピー性皮膚炎に対しては改善効果が認められる
ものの、ニキビに対しては改善効果が充分に発現されな
いことが判る。さらに、アトピー性皮膚炎に対しても、
改善効果は認められるものの、その症状がほとんど消失
された例は極めて少ないことが判る。また、粗糖の抽出
物のみを配合した薬用ローション(比較例2)では、比
較例3に示す薬用ローションと比べると、ややアトピー
性皮膚炎に対する改善効果が認められるものの、充分な
効果ではないことが判る。コガネバナの抽出物と粗糖の
色素成分とを配合した実施例1の薬用ローションでは、
アトピー性皮膚炎、およびニキビのいずれの症状にも極
めて顕著な改善効果が認められることが判る。表2の結
果から明らかな如く、コガネバナの粉砕物又はその抽出
物のみ、或いは粗糖の色素成分のみでは黄色ブドウ球菌
staphylococcus aureus に対する阻害活性が極めて低い
(阻止円が形成されなかった)が、コガネバナ粉砕物又
は抽出物と粗糖の色素成分との混合物(実施例6〜1
0)では阻害活性が極めて高いことが判る。表3の結果
から明らかな如く、粗糖の色素成分のみ(比較例7)で
は5−HETEに対する産出阻害活性が充分に発現され
ないことが判る。また、コガネバナの粉砕物又はその抽
出物と粗糖の色素成分との混合物(実施例6〜10)で
は、粗糖のみ、或いはコガネバナの粉砕物又はその抽出
物のみの場合と比べると、極めて顕著な産出阻害活性が
認められることが判る。As is evident from the results in Table 1, the medicated lotion containing only Scutellaria extract (Comparative Example 1) showed an improvement effect on atopic dermatitis, but an improvement on acne. It turns out that the effect is not sufficiently exhibited. Furthermore, for atopic dermatitis,
Although the improvement effect is recognized, it can be seen that there are very few cases in which the symptoms have almost disappeared. In addition, the medicated lotion containing only the crude sugar extract (Comparative Example 2) showed a slight improvement effect on atopic dermatitis as compared with the medicated lotion shown in Comparative Example 3, but it was not sufficient. I understand. In the medicated lotion of Example 1 in which the extract of Scutellaria and the pigment component of crude sugar were blended,
It can be seen that a remarkable remarkable improvement effect is recognized for both atopic dermatitis and acne. As is evident from the results in Table 2, Staphylococcus aureus was used only in the ground millet of Scutellaria or its extract, or in the pigment component of crude sugar alone.
Although the inhibitory activity against staphylococcus aureus is extremely low (no inhibition circle was formed), a mixture of a millet or extract of Scutellaria and a pigment component of crude sugar (Examples 6-1)
0) shows that the inhibitory activity is extremely high. As is clear from the results in Table 3, it is found that the production inhibitory activity against 5-HETE is not sufficiently expressed only with the pigment component of the crude sugar (Comparative Example 7). In addition, in the case of the mixture of the crushed Scutellaria or the extract thereof and the pigment component of the crude sugar (Examples 6 to 10), the yield is extremely remarkable compared to the case of using only the crushed crude sugar or the crushed Scutellaria or the extract thereof alone. It turns out that the inhibitory activity is recognized.
【0041】[0041]
【発明の効果】以上詳述した如く、この発明はコガネバ
ナ(Scutellaria baicalensis GEORGI)の粉砕物及び/
又はその抽出物と、粗黒糖から抽出された色素成分とを
必須成分として含有してなることを特徴とする皮膚外用
剤であるから、人体に対する安全性が極めて高く、しか
も前記試験例の結果からも明らかな如く、アトピー性皮
膚炎やニキビ、吹き出物等の皮膚疾患に対する症状改善
に極めて有効であるから、これら皮膚疾患に対する症状
の改善・予防を目的に、薬用化粧品、医薬品として、或
いは健常皮膚に美肌化を目的に一般化粧品として、乳幼
児の顔面等にも安心して施用することができるという優
れた効果を奏する。As described in detail above, the present invention relates to a ground product of Scutellaria baicalensis GEORGI and / or
Or an extract thereof, and a skin external preparation characterized by comprising a pigment component extracted from crude brown sugar as an essential component, which is extremely high in safety to the human body, and from the results of the test examples. As is evident, it is extremely effective in improving the symptoms of skin diseases such as atopic dermatitis, acne, pimples and the like. It has an excellent effect that it can be safely applied to the face of infants and the like as a general cosmetic for the purpose of beautiful skin.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 35/78 ABF A61K 35/78 ABFU ADA ADAQ ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification code Agency reference number FI Technical display A61K 35/78 ABF A61K 35/78 ABFU ADA ADAQ
Claims (3)
GEORGI)の粉砕物及び/又はその抽出物と、粗黒糖から
抽出された色素成分とを必須成分として含有してなるこ
とを特徴とする皮膚外用剤。1. Scutellaria baicalensis
An external preparation for skin, comprising as essential components a ground product of GEORGI) and / or an extract thereof, and a pigment component extracted from crude brown sugar.
ることを特徴とする請求項1に記載の皮膚外用剤。2. The external preparation for skin according to claim 1, wherein the pigment component is phenyl glucose.
sis GEORGI)の粉砕物及び/又は抽出物がフラボノイド
化合物を含有してなることを特徴とする請求項1乃至2
に記載の皮膚外用剤。3. The Scutellaria baicalen (Scutellaria baicalen)
3. The crushed product and / or extract of sis GEORGI) comprises a flavonoid compound.
2. The external preparation for skin according to item 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6095740A JP2711630B2 (en) | 1994-04-07 | 1994-04-07 | External preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6095740A JP2711630B2 (en) | 1994-04-07 | 1994-04-07 | External preparation for skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07277942A JPH07277942A (en) | 1995-10-24 |
JP2711630B2 true JP2711630B2 (en) | 1998-02-10 |
Family
ID=14145894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6095740A Expired - Lifetime JP2711630B2 (en) | 1994-04-07 | 1994-04-07 | External preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2711630B2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100639538B1 (en) * | 1996-08-02 | 2007-03-02 | 가부시키가이샤 시세이도 | Composition for enhancing production capacity of hyaluronic acid and preparation method thereof |
KR20020061196A (en) * | 2001-01-15 | 2002-07-24 | 주식회사 코리아나화장품 | Cosmetic compositions containing scutellaria extracts |
KR100418688B1 (en) * | 2001-02-06 | 2004-02-11 | 퓨리메드 주식회사 | The growth inhibition of Propionibacterium acnes for the multiple extracts of herbal medicaments |
JP2002302697A (en) * | 2001-04-06 | 2002-10-18 | Kanebo Ltd | Detergent composition |
DE10139793A1 (en) * | 2001-08-14 | 2003-02-27 | Beiersdorf Ag | Use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and / or for skin protection in the case of sensitive, dry skin |
US7108868B2 (en) | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
US7972632B2 (en) | 2003-02-28 | 2011-07-05 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
US20030165588A1 (en) * | 2002-03-01 | 2003-09-04 | Unigen Pharmaceuticals, Inc. | Identification of free-B-ring flavonoids as potent COX-2 inhibitors |
CN100544715C (en) | 2002-04-30 | 2009-09-30 | 尤尼根制药公司 | As there not being the compositions that replaces B lopps flavone and flavane mixture comprising of therapeutic agent |
JP2004248592A (en) * | 2003-02-20 | 2004-09-09 | Sanpo Kk | Tyrosinase inhibitor and method for producing the same |
BRPI0409179A (en) | 2003-04-04 | 2006-05-02 | Unigen Pharmaceuticals Inc | formulation of dual cyclooxygenase (cox) and lipoxygenase (lox) inhibitors for mammalian skin care |
KR100567431B1 (en) * | 2004-01-08 | 2006-04-04 | 황재관 | Acne treatment or prevention composition containing lignan compound as an active ingredient |
FR2906716B1 (en) * | 2006-10-06 | 2013-05-17 | Clarins Lab | USE OF A COSMETIC COMPOSITION FOR THE CARE OF OIL SKIN. |
KR100761248B1 (en) | 2006-10-12 | 2007-10-04 | 주식회사 유니젠 | Composition for the treatment of atopic dermatitis containing bamboo and golden extract as active ingredients |
CN104130230A (en) * | 2014-06-30 | 2014-11-05 | 施佩蓓 | Baicalein production method |
-
1994
- 1994-04-07 JP JP6095740A patent/JP2711630B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH07277942A (en) | 1995-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2711630B2 (en) | External preparation for skin | |
US8563054B2 (en) | Anti-inflammatory agent | |
JPH0826969A (en) | Cosmetic composition | |
US5556866A (en) | Hair restorer and its preparation | |
JPH07187989A (en) | Extracted solution of perilla frutescens and skin-beautifying cosmetic containing the same | |
JP3118020B2 (en) | Cosmetics | |
JP3091045B2 (en) | Skin cosmetics | |
JP2004331512A (en) | Cosmetic composition | |
JP2003160461A (en) | Skin care preparation | |
JPH07157494A (en) | New isoflavone glycoside and cosmetic containing the same | |
KR102221627B1 (en) | Composition comprising Rhus Semialata extract as active ingredient | |
JPH07252128A (en) | Skin external preparation | |
JP3828163B2 (en) | Anti-inflammatory, anti-itch agent | |
JP2006517180A (en) | A cosmetic composition having a whitening effect, which contains an extract of pursatilla root as a main component | |
JP2004345969A (en) | Tyrosinase inhibitor and bleaching cosmetic using the same | |
JP3091040B2 (en) | Skin cosmetics | |
JPH03127714A (en) | Skin cosmetic | |
JP4579550B2 (en) | Ceramide synthesis accelerator and external preparation for skin | |
JP4105498B2 (en) | A composition effective for prevention and alleviation of symptoms of atopic disease | |
JP3182047B2 (en) | Cosmetic composition containing an ingredient extracted from brown sugar | |
JP5649995B2 (en) | Ceramide production promoter | |
JPH05238925A (en) | External preparation on skin | |
JPH10279490A (en) | Antiinflammatory/anti-itch external preparation | |
JP4402278B2 (en) | Whitening cosmetics | |
JP4037836B2 (en) | Hyaluronidase activity inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081031 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091031 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091031 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101031 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101031 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111031 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121031 Year of fee payment: 15 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121031 Year of fee payment: 15 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131031 Year of fee payment: 16 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |